Royalty Pharma PLC
RPRX Healthcare Biotechnology
Royalty Pharma PLC’s revenue for fiscal 2025 (year ended December 2025) was $2.4 billion, up 5.06% from fiscal 2024. In the quarter to June 2026, revenue grew 16.5%, EPS fell 40.0%, free cash flow grew 31.6% and total debt rose 12.0%, each against the same quarter a year earlier. Dividend growth for five consecutive years.
Follow RPRX
Royalty Pharma PLC (RPRX) EV/Sales
As of 16 October 2026, Royalty Pharma PLC (RPRX) trades at a EV/Sales of 14.0×. Over the past ten years it has ranged from 0.0× (June 2020) to 14.4× (September 2026); the current reading is higher than 99% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 10.5× | 31.35% |
| FY2024 | 8.0× | (2.64%) |
| FY2023 | 8.2× | (19.02%) |
| FY2022 | 10.1× | 7.15% |
| FY2021 | 9.4× | (11.82%) |
| FY2020 | 10.7× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 13.0× | 8.65% |
| Mar 2026 | 12.0× | 14.57% |
| Dec 2025 | 10.5× | 6.01% |
| Sep 2025 | 9.9× | 0.75% |
| 24 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| BNTX BioNTech SE Sponsored ADR compare | 1.8× |
| INCY Incyte Corporation compare | 3.1× |
| ALNY Alnylam Pharmaceuticals, Inc. compare | 6.0× |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | 6.1× |
| GMAB Genmab A/S Sponsored ADR compare | 6.4× |
| ARGX argenex SE compare | 8.9× |
| RPRX Royalty Pharma PLC | 14.0× |
| RVMD Revolution Medicines, Inc. compare | 1,287× |
| ROIV Roivant Sciences Ltd. compare | 2,742× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)